Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Oruka Therapeutics, Inc. (ORKA : NSDQ)

• Company Description    Oruka Therapeutics Inc. is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka Therapeutics Inc., formerly known as ARCA biopharma Inc., is based in WESTMINSTER, Colo. Number of Employees: 68

• Price / Volume Information    Yesterday's Closing Price: $60.61 Daily Weekly Monthly 20 Day Moving Average: 2,461,185 shares Shares Outstanding: 60.31 (millions) Market Capitalization: $3,655.51 (millions) Beta: -0.20 52 Week High: $91.00 52 Week Low: $10.64 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -10.53% -14.90% 12 Week 76.60% 63.26% Year To Date 99.97% 78.02%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 855 OAK GROVE AVENUE SUITE 100 - MENLO PARK,CA 94025 USA ph: 650-606-7910 fax: 720-208-9261 ir@orukatx.com https://orukatx.com

• General Corporate Information    Officers Lawrence Klein - Chief Executive Officer & Director Samarth Kulkarni - Chairman Arjun Agarwal - Senior Vice President; Finance and Treasurer Kristine Ball - Director Carl Dambkowski - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 687604108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/10/26 Share - Related Items Shares Outstanding: 60.31 Most Recent Split Date: 9.00 (0.08:1) Beta: -0.20 Market Capitalization: $3,655.51 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.49 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.05 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/10/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 7.56 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -20.00% vs. Previous Quarter: -6.67% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - -26.16 12/31/25 - -25.48 09/30/25 - -25.97 ROA 03/31/26 - -25.00 12/31/25 - -24.34 09/30/25 - -24.79 Current Ratio 03/31/26 - 23.76 12/31/25 - 22.37 09/30/25 - 16.94 Quick Ratio 03/31/26 - 23.76 12/31/25 - 22.37 09/30/25 - 16.94 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - 8.02 12/31/25 - 9.69 09/30/25 - 11.65 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©